V590 Uses, Dosage, Side Effects and more
The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose. Other features of this vaccine include potential activity with oral administration via a swish-and-swallow protocol. Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786).
| Trade Name | V590 |
| Generic | V590 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
